BUZZ-Delcath Systems rises as co expects wider-than-estimated Q3 revenue

Reuters

Oct 18, 2024

Oct 17 (Reuters) - ** Shares of medical device maker Delcath Systems Inc up 5.8% at $10.06

** Co expects Q3 revenue of $11.2 mln, above analysts' average estimate of $9.45 mln, according to data compiled by LSEG

** Co says it recorded $10 mln in U.S. revenue in Q3 from commercialization of Hepzato Kit, a drug-device combination product for cancer treatment

** DCTH says $10 mln quarterly U.S. revenue milestone triggers $25 mln financing tranche, which it will utilize to support ongoing commercial launch and invest in new trials to expand indications it plans to initiate in 2025

** Co to announce quarterly financial results on Nov. 8

** Up to last close, stock up ~140.98% YTD

(Reporting by Rishab Shaju in Bengaluru)

((Rishab.Shaju@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2476110206"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2476110206\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2476110206?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-18 00:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2476110206","market":"us","top_or_hot":-1,"title":"BUZZ-Delcath Systems rises as co expects wider-than-estimated Q3 revenue","media":"Reuters","content":"<html><body><p>Oct 17 (Reuters) -    ** Shares of medical device maker Delcath Systems Inc    up 5.8% at $10.06</p><p>   ** Co expects Q3 revenue of $11.2 mln, above analysts' average estimate of $9.45 mln, according to data compiled by LSEG </p><p>   ** Co says it recorded $10 mln in U.S. revenue in Q3 from commercialization of Hepzato Kit, a drug-device combination product for cancer treatment</p><p>   ** DCTH says $10 mln quarterly U.S. revenue milestone triggers $25 mln financing tranche, which it will utilize to support ongoing commercial launch and invest in new trials to expand indications it plans to initiate in 2025</p><p>   ** Co to announce quarterly financial results on Nov. 8</p><p>   ** Up to last close, stock up ~140.98% YTD</p><p> (Reporting by Rishab Shaju in Bengaluru)</p><p>((Rishab.Shaju@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Delcath Systems rises as co expects wider-than-estimated Q3 revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Delcath Systems rises as co expects wider-than-estimated Q3 revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-10-18 00:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Oct 17 (Reuters) -    ** Shares of medical device maker Delcath Systems Inc    up 5.8% at $10.06</p><p>   ** Co expects Q3 revenue of $11.2 mln, above analysts' average estimate of $9.45 mln, according to data compiled by LSEG </p><p>   ** Co says it recorded $10 mln in U.S. revenue in Q3 from commercialization of Hepzato Kit, a drug-device combination product for cancer treatment</p><p>   ** DCTH says $10 mln quarterly U.S. revenue milestone triggers $25 mln financing tranche, which it will utilize to support ongoing commercial launch and invest in new trials to expand indications it plans to initiate in 2025</p><p>   ** Co to announce quarterly financial results on Nov. 8</p><p>   ** Up to last close, stock up ~140.98% YTD</p><p> (Reporting by Rishab Shaju in Bengaluru)</p><p>((Rishab.Shaju@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DCTH","symbol_name":"迪卡斯","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2476110206","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2476110206","pubTimestamp":1729183817,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Oct 17  -    ** Shares of medical device maker Delcath Systems Inc    up 5.8% at $10.06   ** Co expects Q3 revenue of $11.2 mln, above analysts' average estimate of $9.45 mln, according to data compiled by LSEG    ** Co says it recorded $10 mln in U.S. revenue in Q3 from commercialization of Hepzato Kit, a drug-device combination product for cancer treatment   ** DCTH says $10 mln quarterly U.S. revenue milestone triggers $25 mln financing tranche, which it will utilize to support ongoing commercial launch and invest in new trials to expand indications it plans to initiate in 2025   ** Co to announce quarterly financial results on Nov. 8   ** Up to last close, stock up ~140.98% YTD ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"DCTH":"迪卡斯"},"translate_title":"BUZZ-Delcath Systems股价上涨，公司预计第三季度收入超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCTH":0.9},"content_text":"Oct 17 (Reuters) -    ** Shares of medical device maker Delcath Systems Inc    up 5.8% at $10.06   ** Co expects Q3 revenue of $11.2 mln, above analysts' average estimate of $9.45 mln, according to data compiled by LSEG    ** Co says it recorded $10 mln in U.S. revenue in Q3 from commercialization of Hepzato Kit, a drug-device combination product for cancer treatment   ** DCTH says $10 mln quarterly U.S. revenue milestone triggers $25 mln financing tranche, which it will utilize to support ongoing commercial launch and invest in new trials to expand indications it plans to initiate in 2025   ** Co to announce quarterly financial results on Nov. 8   ** Up to last close, stock up ~140.98% YTD (Reporting by Rishab Shaju in Bengaluru)((Rishab.Shaju@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}